Podcast: Using Antibodies to Treat Alzheimer’s a No-Brainer

By Marc Dresner, Senior Editor, IBC Life Sciences

While antibody therapies today are most commonly associated with oncology and inflammatory diseases, the next big breakthroughs may be on the neurology front.

Dr. Trudi Veldman, Senior Director of Biologics Generation at AbbVie Bioresearch Center, says deploying bispecifics as a “Trojan Horse” to enhance transport across the blood brain barrier could finally satisfy some extreme unmet needs.

“I see a lot of opportunities around Alzheimer’s, Multiple Sclerosis and Parkinson’s disease.”

“I see a lot of opportunities around neurological diseases, such as Alzheimer’s, Multiple Sclerosis and Parkinson’s disease,” said Veldman.

In this podcast interview for Inside Antibody Engineering, Dr. Veldman explains:

• Why she thinks antibody applications in neurology look so promising

• Where she sees impressive progress elsewhere in the field

• Why Fc receptor biology needs more attention and more!

Listen to the podcast or download a transcript here!

Editor’s note: Dr. Trudi Veldman will be chairing the Antibody Therapeutics for Non-Cancer Indications track at the Antibody Engineering and Therapeutics Conference taking place December 7-10 in San Diego.

Click here for an agenda. 

Or for more information visit: www.ibclifesciences.com/antibodyeng

(Ps. SAVE $100 when you register with code D15172BLOG!)

ABOUT THE AUTHOR/INTERVIEWER
Marc Dresner is sr. editor and special communication project lead with IBC Life Sciences. He is the former executive editor of Pharma Market Research Report, a publication for market research professionals specializing in pharmaceuticals and life sciences. He may be reached at mdresner@iirusa.com. Follow him @mdrezz.

Share this article with your social network, just click below to share now!

Share |

Six Ways to Accelerate Your Antibody Research, Discovery Efforts and Clinical Programs

What tools are we giving you to do this at Antibody Engineering in Huntington Beach in December?

1. 1) Find new antibody targets beyond the low-hanging fruit - strategies for targeting difficult antigens
2. 2) Learn about development strategies for ADCs, bispecifics, fusions, antibody combinations and other complex molecules/next-generation antibodies
3. 3) Exploit immune checkpoints for target discovery, new agent design and preclinical/clinical development
4. 4) Engineer improved antibody developability - expression, solubility and polyreactivity
5. 5) Develop antibody therapeutics for multiple non-cancer indications including diabesity, autoimmune disease and multiple sclerosis
6. 6) Get the latest data and lessons learned from numerous preclinical and clinical antibody therapeutic projects

How will you get in-depth insights into these topics and from whom?  Download the agenda to find out.  If you'd like to join us this December 8-12 at Antibody Engineering and Therapeutics, as a reader of this blog, when you register to join us and mention code XD14172BLOG, you can save 20% off the standard rate.

Share this article with your social network, just click below to share now!

Share |

Video Highlights from Last Year’s Antibody Engineering & Therapeutics Meeting

Entering its 25th consecutive year, IBC's Antibody Engineering & Therapeutics is the #1 meeting of its kind, gathering antibody researchers and executives from around the world under one roof to exchange ideas and results in antibody engineering and development, immunobiology and next-generation binders.


Accelerate your antibody research, discovery efforts and clinical programs by joining your peers at IBC’s 25th Antibody Engineering meeting, taking place December 7-11, 2014 in Huntington Beach, CA.

View our preliminary agenda today.

New for 2014, hear world-renowned scientists and academics discuss recent groundbreaking approaches to exploit antibodies for developing novel medicines and vaccines. Also, benchmark your development pipeline by hearing exciting results and lessons learned from safety and efficacy studies covering the most cutting-edge antibody therapeutics now in preclinical/clinical development.

What are we excited about for this year's event?

• - Multiple sessions to help you find new antibody targets beyond the low hanging fruit
• - Big emphasis on immunotherapeutic strategies and targets including immune checkpoints
• - More sessions and case studies focused on non-cancer antibody therapeutics and targets
• - Learn how to “design in” developability and manufacturability of your molecules
• - 2 new workshops on “The Nuts & Bolts of Antibody Development” and “Precision Targeting”
• - More preclinical and clinical data than ever before!

Register by this Friday, June 27 to get the lowest rates of the year!  Find out more and register here.  And as a reader of this blog, when you register to join us and mention code XD14172BLOG, you can save 20% off the standard rate.

Share this article with your social network, just click below to share now!

Share |

Antibody Engineering & Therapeutics Call For Speakers

The deadline for speaker abstract submissions for the Antibody Engineering & Therapeutics Event is Friday, April 25, 2014. To submit a proposal, you will be asked to select the conference topic you are interested in, provide a 100-150 word summary of your proposed talk and provide your full contact details.

We are looking for presentations in the following topic areas:

• • Going Deep: Finding Good Antibody Targets beyond the Low Hanging Fruit - Antibodies against Difficult Targets for Therapeutics
• • Going Broad: High Quality Research Antibodies against the Proteome: TFs and other Binders
• • Antibody Effector Functions
• • Immunocytokine Engineering
• • Antibody-based Therapeutics for Diabesity: The Link between Diabetes and Obesity
• • Antibody Therapeutics for Non-Cancer Indications (Alzheimer’s, Infectious Disease, Autoimmune, Pediatric and other Diseases. MOA Studies and Biological Understanding)
• • Next Generation Sequencing: Human Antibody Repertoires and Other Applications
• • Immune Checkpoints: Target Discovery and New Agent Design for Antibody Therapy
• • Immune Checkpoints: Preclinical and Clinical Development Case Studies
• • Combination Antibodies and mAb Fusions (Antibody Mixtures, Fusions w/Cytokines or Other Biomolecules, ADCs, Combined Binding Domains to Create New Modalities)
• • Targeted Immunomodulation in Cancer: Antibody-conjugated Cytokines and Adjuvants
• • Antibody Biophysical Characterization/Preclinical Characterization (What to assess, How to assess and Why?)
• • Research-Based Process Development of Antibodies (Discovery stage evaluations of formulation, aggregation, structure/stability, antibody production and purification )
• • Preclinical and Clinical Case Studies of Antibody-based Therapeutics (Including PK/ADME data, discussion of clinical challenges, failure analysis)
• • Antibody Targeting and Alternative Delivery (Going beyond tumor-targeting: Targeting to specific cells, tissues and organs)
• • Antibody Modeling and Computational Design/Knowledge-based Design of Antibodies
• • Preclinical and Clinical Case Studies: Emerging Targets, New Approaches
• • Why is Choosing Targets for Bispecific Antibodies so Difficult?

Submit your proposals here.

Are you interested in exhibiting?  Find out how.

Antibody Engineering & Therapeutics will take place December 7-11, 2014 in Huntington Beach, California.  Register now for the lowest rates of the year.  You can also sign up for the latest updates on this year's program.

Share this article with your social network, just click below to share now!

Share |